Inovio Pharmaceuticals, Inc. (INO) Dividend History

Company News

• Better Buy: Inovio Pharmaceuticals vs. Novavax

  Both biotechs have been struggling for a while, but there might be some hope for them.

  The Motley Fool

  Featured Companies: NVAX
• DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst

  Stephens initiated coverage on INOVIO Pharmaceuticals Inc (NASDAQ:INO), noting the company’s diversified clinical pipeline of therapeutic and vaccine candidates, which the company is looking to advance eight additional clinical-stage candidates.  The analyst writes that the FDA considered lead program INO-3107 Phase 1/2 clinical trials sufficient for the Accelerated Approval Program. If approved, INO-3107 could be the first non-surgical treatment for recurrent respiratory papillomatosis (RRP).  RRP is a rare chronic disease caused by the human papillomavirus. In RRP, wart-like tumors grow on and around vocal cords. FDA marketing application submission for INO-3107 ...Full story available on Benzinga.com

  Benzinga
• Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript

  INO earnings call for the period ending March 31, 2024.

  The Motley Fool
• Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates

  Equillium (EQ) delivered earnings and revenue surprises of 52.94% and 16.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: EQ
• This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?

  Can the biotech succeed after a string of failures?

  The Motley Fool